Chronic thromboembolic pulmonary hypertension and balloon pulmonary angioplasty - Where are we in 2024?
Curr Probl Cardiol
; 49(5): 102481, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38401824
ABSTRACT
Pulmonary endarterectomy (PEA) is the first-line treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, some patients with CTEPH are considered inoperable, and in the last decade, balloon pulmonary angioplasty (BPA) has emerged as a viable therapeutic option for these patients with prohibitive surgical risk or recurrent pulmonary hypertension following PEA. Numerous international centers have increased their procedural volume of BPA and have reported improvements in pulmonary hemodynamics, patient functional class and right ventricular function. Randomized controlled trials have also demonstrated similar findings. Recent refinements in procedural technique, increased operator experience and advancements in procedural technology have facilitated marked reduction in the risk of complications following BPA. Current guidelines recommend BPA for patients with inoperable CTEPH and persistent pulmonary hypertension following PEA. The pulmonary arterial endothelium plays a vital role in the pathophysiologic development and progression of CTEPH.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Angioplastia com Balão
/
Hipertensão Pulmonar
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article